Friday, July 10, 2026

biotech · Breast Cancer · Pleural carcinosis · SANA

Sana Biotechnology

Sana Biotechnology is a biotech organization headquartered in Seattle, USA. It trades on NYSE under ticker SANA. Primary therapeutic focus areas include Breast Cancer, Pleural carcinosis, Parkinson’s Disease, Graves' dis

188 E Blaine St, Suite 400, Seattle, Washington 98102, US HQ
2018 Founded
265 Employees
Public company Type
SANA · NYSE Ticker
Company details
Status
Public
HQ
188 E Blaine St, Suite 400, Seattle, Washington 98102, US
Founded
2018
Employees
265
Programs
19
Drugs
22
Patents
136
Clinical program

SC262

Phase 1 · small molecule · Non Hodgkin's Lymphoma

SC262 for Non Hodgkin's Lymphoma is a Phase 1 program (small_molecule) at Sana Biotechnology with 1 ClinicalTrials.gov record(s).

← All Sana Biotechnology projects Phase 1 small molecule active

Internal code SC262-101

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Sana Biotechnology
Phase
Phase 1
Modality
small_molecule
Indication
Non Hodgkin's Lymphoma
Status
active
Trials
1

Clinical trials